The pharmacokinetic profile of plasma-derived mannan-binding lectin in healthy adult volunteers and patients with Staphylococcus aureus septicaemia
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationScand. J. Infect. Dis. 2008, 40(1):44-8
AbstractMannan-binding lectin (MBL) is a member of the innate immune system, and MBL-deficiency affects 10-15% of Caucasians. With development of a plasma-derived MBL, substitution has become a therapeutic option in diseases associated with MBL insufficiency. The pharmacokinetics of injected MBL is weakly described, particularly in patients with infectious diseases. The pharmacokinetic profile of MBL following administration of 0.08 mg/kg to 20 healthy MBL-deficient volunteers and 0.2 mg/kg to 2 patients with Staphylococcus aureus septicaemia was established. In the volunteers, the maximal concentration was 2849 microg/l; the mean half-life (T(1/2)) was 69.6 h (14.6-114.9 h). The normalized clearance was 9x10(-6) l/minxkg, and the mean residence time was 82 h. In the patients the serum-MBL versus time curves were similar to those in the volunteers, and T(1/2) values were 36 and 40 h. In conclusion, MBL is distributed into a median volume of 3.4 l similar to the plasma volume, and the elimination in septicaemic patients was within the range of the controls. Due to the large individual variation in T(1/2), we recommend that MBL therapy, with respect to dose and infusion intervals, is based on the chosen therapeutic target (> or =1000 microg/l) and MBL serum determinations following the first infusion.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Infusion of plasma-derived mannan-binding lectin (MBL) into MBL-deficient humans.
- Authors: Valdimarsson H
- Issue date: 2003 Aug
- Human plasma-derived mannose-binding lectin: a phase I safety and pharmacokinetic study.
- Authors: Valdimarsson H, Vikingsdottir T, Bang P, Saevarsdottir S, Gudjonsson JE, Oskarsson O, Christiansen M, Blou L, Laursen I, Koch C
- Issue date: 2004 Jan
- Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitution in children with chemotherapy-induced neutropaenia.
- Authors: Frakking FN, Brouwer N, van de Wetering MD, Budde IK, Strengers PF, Huitema AD, Laursen I, Houen G, Caron HN, Dolman KM, Kuijpers TW
- Issue date: 2009 Mar
- Low mannose-binding lectin function is associated with sepsis in adult patients.
- Authors: Eisen DP, Dean MM, Thomas P, Marshall P, Gerns N, Heatley S, Quinn J, Minchinton RM, Lipman J
- Issue date: 2006 Nov
- Low Mannan-binding lectin serum levels are associated with complicated Crohn's disease and reactivity to oligomannan (ASCA).
- Authors: Schoepfer AM, Flogerzi B, Seibold-Schmid B, Schaffer T, Kun JF, Pittet V, Mueller S, Seibold F
- Issue date: 2009 Oct